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Effects of Epac1 on Diabetic Retinal Inflammation
Abstract
An ever-growing body of research suggests that inflammation is one of the primary causes of diabetic
retinopathy, as the inflammation can lead to insulin resistance. Beta-adrenergic receptor agonists can
reduce the inflammation in human retinal endothelial cells (HRECs), but are not a viable treatment due to
systemic effects. Epac1 lies downstream of beta-adrenergic receptor signaling, and it may have the
capability to reduce inflammation by acting as an alternative pathway for beta-adrenergic receptor
agonists to block inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and
interleukin-1 beta (IL-1B). We hypothesized that the Epac1 agonist will decrease cytokine levels, leading to
improved insulin signal transduction in the retina.
HRECs were grown in normal (5mM) or high glucose (25mM). Some cells were not treated with the Epac1
agonist and serve as controls. Western blotting was done using primary antibodies for total and
phosphorylated insulin receptor substrate-1 (IRS-1), insulin receptor (IR) and Akt, as well as beta actin as
a control for loading. Anti-Rabbit IgG/HRP was used for secondary antibodies. ELISA analyses were done
for protein levels of TNF-alpha and IL-1B. We are not done with data analyses, but we expect to find that
Epac1 will increase insulin receptor and Akt phosphorylation, while reducing TNF-alpha and IL-1B levels.
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ABSTRACT
An ever-growing body of research suggests that inflammation is one of the primary causes
of diabetic retinopathy, as the inflammation can lead to insulin resistance. Beta-adrenergic receptor
agonists can reduce the inflammation in human retinal endothelial cells (HRECs), but are not a
viable treatment due to systemic effects. Epac1 lies downstream of beta-adrenergic receptor
signaling, and it may have the capability to reduce inflammation by acting as an alternative
pathway for beta-adrenergic receptor agonists to block inflammatory cytokines such as tumor
necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1B). We hypothesized that the Epac1
agonist will decrease cytokine levels, leading to improved insulin signal transduction in the retina.
HRECs were grown in normal (5mM) or high glucose (25mM). Some cells were not
treated with the Epac1 agonist and serve as controls. Western blotting was done using primary
antibodies for total and phosphorylated insulin receptor substrate-1 (IRS-1), insulin receptor (IR)
and Akt, as well as beta actin as a control for loading. Anti-Rabbit IgG/HRP was used for
secondary antibodies. ELISA analyses were done for protein levels of TNF-alpha and IL-1B. We
are not done with data analyses, but we expect to find that Epac1 will increase insulin receptor and
Akt phosphorylation, while reducing TNF-alpha and IL-1B levels.
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